Company / Operating Cash Flow
Arcadia Biosciences, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$9.6M
FY2025
5-year range
-$30.2M / -$9.6M
FY2021-FY2025
Trend
+37.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$30M in FY2021 to -$10M in FY2025.
Based on SEC 10-K filings.
-$10M in FY2025.
Improved from -$14M to -$10M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 37.1% year-over-year.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 7.60 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$9.6M | +37.1% |
| FY2024 | -$15.3M | -9.4% |
| FY2023 | -$14.0M | +46.0% |
| FY2022 | -$25.9M | +14.4% |
| FY2021 | -$30.2M | -75.7% |
| FY2020 | -$17.2M | -26.2% |
| FY2019 | -$13.6M | +2.4% |
| FY2018 | -$14.0M | +18.1% |
| FY2017 | -$17.1M | -12.9% |
| FY2016 | -$15.1M | -2.2% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026